CD8^(+)T细胞在肿瘤免疫中的研究进展  

Research progress of CD8^(+)T cells in tumor immunity

作　　者：纪元 陈明洋 JI Yuan;CHEN Ming-yang(Department of Oncology,The First Hospital of China Medical University,Shenyang 110001,China)

机构地区：[1]中国医科大学附属第一医院肿瘤内科,辽宁沈阳110001

出　　处：《解剖科学进展》2024年第4期440-442,共3页Progress of Anatomical Sciences

基　　金：国家自然科学基金青年基金(81901846)。

摘　　要：在过去的十年中,免疫疗法对临床肿瘤学产生了重大影响。T细胞一直是操纵内源性抗肿瘤免疫治疗的主要焦点,因为它们具有选择性识别来自所有细胞区室中蛋白质肽的能力,具有直接识别和杀死抗原表达细胞的能力(通过CD8效应T细胞),以及协调各种免疫反应的能力(通过CD4辅助T细胞),其整合了适应性和先天性效应器的机制。CD8^(+)T细胞在肿瘤微环境中发挥着重要的作用,是发挥杀伤作用的主要承担者。因此,本文聚焦CD8^(+)T细胞在肿瘤免疫中的作用,主要阐述针对CD8^(+)T细胞研究的最新进展,为肿瘤免疫治疗提供新的见解。Immunotherapy has had a significant impact on clinical oncology over the past decade. T cells have been the main focus for manipulating endogenous anti-tumor immunotherapy because of their ability to selectively recognize protein peptides from all cellular compartments. Their ability to recognize and kill antigen-expressing cells directly(via CD8 effector T cells), and the ability to coordinate various immune responses(via CD4 helper T cells), which integrate the mechanism of adaptive and innate effectors. CD8^(+)T cells play an important role in the tumor microenvironment and are the main bearers of the killing effect. Therefore, this article focuses on the role of CD8^(+)T cells in tumor immunity, expounds the latest progress in the research of CD8^(+)T cells mainly, and provides new insights for tumor immunotherapy.

关 键 词：肿瘤免疫治疗 临床肿瘤学 肿瘤微环境 抗原表达 免疫疗法 免疫反应 选择性识别 T细胞 

分 类 号：R730.2[医药卫生—肿瘤]